Board of Directors

Dr. Vin Menon is a veteran in the technology services industry, who can be credited with the strategic direction behind several disruptive technology companies. In the corporate world, he has held various leadership positions at multinational corporations like HP & Compaq with global responsibilities. Driven by his passion for technology and innovation, Dr. Menon has been a forerunner in technological innovation and has helped create the business ecosystem of disruptive technologies and high-growth companies. His experience has helped him in the technology space as an entrepreneur and advisor, leading several startups from inception to meteoric growth across continents. Dr. Menon’s proven track record of setting up motivated and high caliber teams in the technology and services industry, establishing development centers from scratch to scale, and building company competencies led him to being awarded ‘Entrepreneur of the Year 2012’ by Rotary-ASME, ‘Outstanding Entrepreneur Award 2011’ by APEA, the ‘Spirit of Enterprise 2010’ by SOE Singapore. Dr. Menon was also selected as a ‘Leading Indian Entrepreneur of the Year 2010’ by the Singapore Indian Chamber of Commerce.

From the years 2021 to 2023 he co- founded and served as Strategic Advisor to CGCX, a Fintech, decentralized finance, and digital assets platform, where he provided strategic advisory services and growth initiatives. He currently serves as Chief Executive Officer of AQUAE Impact (AQUAE Impact Exchange Co. L.L.C / AQUAE Impact), a sustainable financial and environmental assets platform that uses blockchain technology and artificial intelligence, which he co-founded and currently forms part of its executive leadership providing oversight of product and sustainability initiatives. He also currently serves as Chief Executive Officer of AQUAE Labs Pte Ltd, which is the research and development and technology arm of AQUAE Impact, where he provides product and technology leadership, measurement, reporting, and verification of environmental credits. Additionally, he currently occupies the role of Strategic Advisor of TechyTrade FZ-LLC, which is a bitcoin-backed company that operates in the digital asset and treasury innovation space. Dr. Menon is also a champion of techno-preneurship and was serving on the Board of Directors of the Spirit of Enterprise (SOE) and the Mentoring Programme under Action Community for Entrepreneurship (ACE) by SPRING Singapore. Moreover, he completed his bachelor’s degree in computer applications from India, with first-class honors. He has also completed the following programs: Advanced Management Program (AMP) at NTU-Berkeley (Haas Business School, California) and Advanced Management Program (AMP) at The Wharton School (University of Pennsylvania, USA) specialized in Finance. Dr. Menon obtained an EMBA from the Nanyang Technological University (NTU) in Singapore. Lastly, he completed his PhD, Blockchain for Impact in Healthcare from The Open International University for Complementary Medicine in collaboration with Al-Farabi Kazakh National University, Kazakhstan 2019.

We believe that these experiences provide Dr. Menon with the skills necessary to lead the Company as its Chief Executive officer and members of the board, including overseeing the Company’s strategy, operations, financial performance, and overall corporate governance.

Amir Dossal is a visionary leader and social entrepreneur dedicated to driving sustainable development through innovative partnerships and global collaboration. A pioneer in forging impactful alliances, Mr. Dossal has co-founded several groundbreaking initiatives, including the Pearl Initiative, Blockchain Commission for Sustainable Development, and the Global Mental Health Task Force. He is a founding Commissioner of the Broadband Commission for Sustainable Development and has served as a Distinguished Fellow at the World Economic Forum’s Centre for Health and Healthcare. He has curated and published Vision for the Future, a digital anthology showcasing insights from global leaders and changemakers, reflecting his commitment to inspiring collective actions. With over 25 years of service at the United Nations, Mr. Dossal’s legacy includes establishing the UN Fund for International Partnerships in 1998 to manage the historic $1 billion gift from Ted Turner and serving as the UN Focal Point for partnerships. During his tenure, he spearheaded numerous initiatives which have strengthened global governance, supported conflict recovery, and mobilized billions in resources for sustainable development.

Mr. Dossal’s work spans diplomacy, international development, and impact-driven innovation, with a proven track record of uniting diverse stakeholders to address global challenges. A passionate advocate for women’s empowerment, media engagement in sustainable development, and technology-driven social innovation. He is also a champion of the UN’s Safe Ground Campaign. His diplomatic acumen and deep understanding of international affairs have enabled him to manage complex projects in emerging markets and foster regional cooperation. Recognized globally for his contributions, Mr. Dossal has received numerous accolades, including ‘2010 Humanitarian Award’ from the UN Association of New York, ‘2010 Ambassador for Peace and Sport’, ‘2015 Humanitarian Innovation Award’ to Mr. Dossal and his son, Zecki, for intergenerational partnerships, ‘2016 Outstanding Achievement Award’ by the ICAEW for addressing global challenges, and ‘2017 Ellis Island International Medal of Honor’. From October 2021 to August 2023, he was an Independent Director and member of the Audit Committee, the Governance Committee, and the Compensation Committee of Majic Wheels Corp, a FinTech and Software Development company. From November 2021 to April 2022, he was a consultant for EarthX, a not-for-profit global environmental organization dedicated to addressing the impact of climate change on the environment. From August 2022 to August 2023, he was a member of the Clinical and Scientific Advisory Board of Burjeel Holdings PVT Ltd., a private healthcare services provide in the United Arab Emirates. Since September 2010 he has served and continues to serve as a member of the Executive Committee and member of the Board of Governors of Pearl Initiative, a United Arab Emirates based not-for-profit company, which he co-founded, to improve corporate accountability and transparency in the Gulf Region. He has served as President and Chief Executive Officer of the Global Partnerships Forum, a United States based not-for-profit knowledge platform to build partnerships for the Sustainable Development Goals since October 2010, a position in which he continues to serve. Mr. Dossal also currently serves as Executive Vice Chairman of Blockchain Commission for Sustainable Development, a not-for-profit to engage the public and private sectors advance by utilizing blockchain technologies since September 2017 and continues to serve in that role. Since August 2023 he has served as Chairman of AQUAE Impact, where he helps businesses navigate climate and environmental pressures by adopting the Sustainable Development Goals, creating measurable impact through innovative ALCI solutions, and continues to serve in that role. Since May 2025 to this date, Mr. Dossal has served as Chairman of SDG News, a media platform dedicated to informing, inspiring, and accelerating progress on the Sustainable Development Goals, and Vice Chairman of Global Resilience Partners, an advisory firm specializing in partnerships to advance climate, nature, and resilience solutions.

We believe these experiences provide Mr. Dossal with the skills necessary to contribute meaningfully to oversight of Apimed’s strategy, financial reporting, governance, and risk management.

Erik Emerson is the President of Apimeds Pharmaceuticals US, Inc., a clinical-stage biopharmaceutical company specializing in innovative treatments for osteoarthritis. He assumed the role of CEO in September 2023. His experience extends from building commercial organizations to extensive fundraising and M&A transactions.

Before joining Apimeds, Mr. Emerson served as Chief Commercial Officer at Odyssey Health, Inc., where he was instrumental in driving commercial strategies. He also held the position of Chief Commercial Officer at Mezzion Pharmaceuticals, Inc., contributing to the company's growth and market presence.

In 2013, Mr. Emerson co-founded Symplmed Pharmaceuticals LLC and served as its President and Chief Executive Officer, leading the development and commercialization of pharmaceutical products. His earlier career includes roles as Senior Director of Commercial Development at XOMA Corporation and Marketing Director at Gilead Sciences, Inc., where he gained extensive experience in product development and marketing within the pharmaceutical industry.

Mr. Emerson holds an undergraduate degree from the University of Oregon. Erik is the father of 4 and enjoys golf, family, and the beach during his free time.

Elona is an experienced public company board member, Compensation Committee Chairwoman, and Audit Committee member.

Elona is a respected strategic leader in corporate strategy, and M&A having led over $10 billion of merger and acquisition transactions resulting in significant deal premiums and increases in shareholder value and a thought leader in corporate governance.

Elona has significant leadership experience and an operational record of success in product life cycle management from R&D through commercialization, capital raising experience, and therapeutic expertise in oncology, CNS, and cell and gene therapy. Elona's strong financial background and operational expertise are reflected in her election as the Compensation Committee Chair, and Audit Committee member of Cardax, Inc., a public company developing safe, anti-inflammatory medicines. Elona currently serves as the General Counsel of Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through unbiased proteomics analysis. In her prior role, Elona served as the General Counsel for Selecta Biosciences, an immune tolerance company, developing novel treatments in gene and cell therapy and rare diseases during which she negotiated several gene therapy collaborations in rare diseases, and helped lead several financing rounds in excess of $75 million. In a prior role, Elona served as the General Counsel and SVP of Government Relations for ARIAD Pharmaceuticals, a rare disease oncology company, during which she led the successful creation of the Government Affairs function, and the strategic sale of the Company for over $5 Billion. Prior to that, Elona held roles of increasing responsibility at King Pharmaceuticals, Inc., acquired by Pfizer, and Avanir Pharmaceuticals, Inc. acquired by Otsuka Pharmaceuticals.

Elona is a founding co-chair of the Women Leaders in Life Sciences conference. Elona is passionate about the arts, educational initiatives improving public school education, and raising the profiles of women and minorities in the legal field and the boardroom.

Mr. Jakap Koo has served as a director since October 2023. Mr. Koo is also the Chief Executive Officer and President of both Apimeds Korea and its parent company, Inscobee Inc. (KRX: 006490), where he has served since March 2020.

Before joining Apimeds Korea and Inscobee, from March 2015 to December 2019 he served as the Chief Executive Officer at Lotte Auto Lease Co. Ltd., where he grew company revenue through various financial services of car rental, installment payment, automobile leasing and investment banking to both B2B and B2C clients. Mr. Koo has spent more than 35 years mostly as C-level executives in various financial institutions and IT companies. His management and operational experiences cover banking, asset management, venture capital, private equity, and biotechnology companies. Mr. Koo has received his MBA from Stern School of New York University. He graduated from Seoul National University majoring in Law.

Carol O’Donnell has over four decades of financial services and investment experience. She has served as a key member of executive teams in the capacity of CEO, General Counsel, CCO, and independent director. Carol brings a comprehensive understanding of how traditional corporate environments intersect with the entrepreneurial strategies necessary for business expansion.

Carol O’Donnell has served as a director since October 2023. Ms. O’Donnell is currently a Director and Member of the Audit Committee of Sono-Tek Corporation (NASDAQ: SOTK), where she has served since November 2018. Prior to that, she served as General Counsel to Boothbay Fund Management LLC, a registered investment adviser, from December 2019 through May 2021. Ms. O’Donnell joined Protégé Partners and MOV37, an industry leading firm investing in and seeding smaller and emerging hedge fund managers in April 2016 and has served as Chief Executive Officer since January 2018.

Prior to joining Protégé Partners and MOV37, Ms. O’Donnell was the Director of Legal and Compliance with DARA Capital US, Inc., a Swiss-owned boutique registered investment advisory and wealth management firm from January 2013 to March 2016. She served as General Counsel and Chief Compliance Officer of each of the Permal Group and Framework Investment Group from June 2004 through February 2011 and from January 2002 to May 2004, respectively. She also served as a director of FSI Low Beta from 2012 to 2021. Ms. O’Donnell was named one of the Top 50 Women in Hedge Funds in September 2018 and is currently admitted to practice law in the State of Connecticut.

Ben is the President of inThought Research, Inc, a provider of decision support for life sciences companies and investors. After completing his studies at MIT, Stanford, UCSD, and Australia National University, Dr. Weintraub was a sell side biotech analyst and independent research provider prior to forming inThought in 2009.

Dr. Weintraub has served as a director since October 2023. Dr. Weintraub currently serves as the President of inThought Research (“inThought”), a healthcare business intelligence consulting firm which he founded in 2009. inThought provides business development support, competitive intelligence monitoring, medical conference coverage, and other services both to professional investors and to pharma / biotech companies.

Dr. Weintraub has also served as the Chief Scientific Officer of inPhronesis since 2018. After completing his training in immunology and biochemistry, Dr. Weintraub co-founded Biotech Tracker, an online tool for investors, where he served as a financial analyst from 2000 to 2008. From 2006 to 2008, Dr. Weintraub served as an analyst at Reuters Insight, providing analysis of drug development and trends in medicine to professional investors. Dr. Weintraub served as a licensed security analyst with Variant Research from 2005 to 2006. From 1999 to 2000, Dr. Weintraub was senior scientific editor for the biology research journals Cell and Molecular Cell.

Dr. Weintraub performed biochemistry and immunology research at Stanford University and at the John Curtin School of Medical Research in Canberra, Australia. He earned his doctorate in Biology from the University of California, San Diego, and a Bachelor of Science in Life Science from the Massachusetts Institute of Technology.